Professor, Computer Science
Dr. Batzoglou research focuses on computational genomics: developing algorithms, machine learning methods, and systems for the analysis of large scale genomic data. He received a BS in Computer Science, BS in Mathematics, and MEng in EE&CS from MIT in June 1996, and a PhD in Computer Science from MIT in June 2000. He joined Stanford in 2001. He is a recipient of the Sloan Fellowship, the NSF Career Award, Technology Review's "Top 100 Young Technology Innovators" Award in 2003, and the ISCB Innovator Award in 2016. He is also co-founder of DNAnexus.
Assistant Professor, Radiation Oncology
Dr. Diehn is an expert in genomics-based biomarkers who has developed a promising new blood test for monitoring and early detection of cancers. Dr. Diehn’s work is focused on genomics and stem cell biology. The Diehn laboratory focuses on two main areas: 1) cancer stem cell biology and its implications for therapy and 2) development of genomics-based biomarkers for identifying the presence of cancer cells, predicting outcome, and predicting response to therapy. Dr. Diehn works primarily with cancers of the lung and breast. He is currently advancing his work through a variety of clinical trials.
Director, Stanford Clinical Cancer Genetics & Genomics Programs;
Associate Professor, Medicine (Oncology), Genetics and of Pediatrics
Dr. Ford is a medical oncologist and geneticist at Stanford, devoted to studying the genetic basis of breast and GI cancer development, treatment and prevention. Dr. Ford's research goals are to understand the role of genetic changes in cancer genes in the risk and development of common cancers. He studies the role of the BRCA1, BRCA2, p53 and CDH1 tumor suppressor genes in DNA repair, and uses techniques for high-throughput genomic analyses of cancer to identify molecular signatures for targeted therapies. Recently, his team has identified biomarker signatures of timor DNA repair deficiencies and used these to predict patient responses in clinical trials at Stanford and nationally using "PARP inhibitors" for the treatment of women with "triple-negative" breast cancer. Dr. Ford is employing Next-Generation Sequencing to identify novel inherited germline DNA mutations in families with a predisposition to cancer. He runs the Stanford Cancer Genetics Clinic, that sees patients for genetic counseling and testing of hereditary cancer syndromes, and enters patients on clinical research protocols for prevention and early diagnosis of cancer.
Director, Stanford Women’s Clinical Cancer Genetics Program;
Associate Professor, Medicine and of Health Research and Policy
Dr. Kurian’s research focuses on the identification of women with elevated breast and gynecologic cancer risk, and on the development and evaluation of novel techniques for early cancer detection and risk reduction. She has published 84 peer-reviewed articles, including several in high-impact journals such as JAMA, Journal of Clinical Oncology, and Journal of the National Cancer Institute. As Director of the Stanford Women’s Clinical Cancer Genetics Program, her practice centers on women at high risk of developing breast and gynecologic cancers. Dr. Kurian serves on several national committees that advance the clinical and research mission of women’s cancer genetics: she develops evidence-based practice guidelines as a member of the National Comprehensive Cancer Network, and she recently led the American Society of Clinical Oncology’s Scientific Program Committee for Cancer Epidemiology and Prevention.
Postdoctoral Fellow, Department of Pathology
Dr. Lal's research focuses on developing and applying machine-learning methods to understand genomic data. Cancer evolves through many kinds of changes in our genomes, including mutations in specific genes, deletion of large segments of DNA, or subtle changes in gene activity. High-throughput experiments based on DNA sequencing allow us to measure these changes, but complex computational methods are required to analyze such datasets and derive insights about cancer evolution. Currently, Dr. Lal is using sequencing and machine learning to study the differences between the genomes of BRCA and sporadic breast tumors. Understanding the unique properties of BRCA tumors can reveal the specific pathways by which BRCA mutations lead to risk of cancer, and can help develop specialized treatment and monitoring for BRCA carriers.
Director, Stanford Cancer Institute
George E. Becker Professor of Medicine
Professor of Medicine (Oncology and Hematology)
and, by courtesy, of Chemical and Systems Biology
Dr. Mitchell’s research relates to the development of new therapies for hematologic malignancies. She is interested in preclinical proof-of-principle studies on mechanisms that induce cell death and on metabolic targets involving nucleic acid biosynthesis in malignant cells. She is also interested in the translation of these studies into clinical trials. Dr. Mitchell received the Stohlman Award from the Leukemia & Lymphoma Society and has been chair of the Medical and Scientific Affairs Committee and a Scholar of the Society. She is a member of the Institute of Medicine of the National Academy of Sciences, has served as president of the American Society of Hematology (ASH), and has authored more than 130 peer-reviewed articles.
Director of Sequencing, Department of Pathology;
Director, Sequencing Service Center;
Co-Director, Stanford Genome Training Program;
Associate Professor, Pathology and of Genetics
Dr. Sidow’s laboratory combines bench experiments with computer analysis—it is both a ‘dry’ lab and a ‘wet’ lab. The lab’s interests range widely across questions in molecular evolution, population genetics, cancer, and gene regulation. The main data engine in Dr. Sidow’s research is DNA sequencing, in the two main contexts in which sequencing is applied: Discovery of variation (such as de novo mutations in children or somatic mutations in cancer) or as a quantification tool in experimental assays that address, for example, mechanisms of gene regulation. Recent specific research interests include the application of evolutionary principles to cancer progression. Dr. Sidow has a track record of publishing studies revolving around DNA sequence evolution and function in high impact journals. He routinely advises consulting clients in matters of DNA sequencing technologies and applications and has served on multiple national advisory panels for the NIH and the DOE
We know it is possible. We know that cutting-edge scientific research being done today will bring about the therapies, cures and preventative treatments that will save the lives – and improve the quality of life – of millions of BRCA-positive individuals tomorrow.